- BRSF signed MOU with leading provider of digital therapeutics for mental health sector to use data, AI to advance work in mental health disorders
- Company will provide proprietary NeuroCap, NeuroEEG devices to collect, transfer data from patients
- Collaboration could expand into a number of clinical and commercial applications
Brain Scientific (OTCQB: BRSF), a commercial-stage, health-care company developing products related to the brain including neurology, AI and machine learning, has signed a memorandum of understanding (“MoU”) with Ehave Inc. (OTC: EHVVF), a provider of digital therapeutics for the mental health sector (https://ibn.fm/ktiLG). The two companies aim to collaborate by using data and AI to correlate biomarkers to identify chronic pain, depression (major and persistent), PTSD, bipolar disorder, general anxiety, ADHD and schizophrenia.
Brain Scientific and Ehave will team up to leverage graph-based AI and linked data protocols to develop neural net algorithms. These algorithms could be used to upload already trained neuronet into a specialized chip that Brain Scientific develops into a temporary e-tattoo or electrodes connected to the micro EEG positioned behind a patient’s ear. The brain e-tattoo is the BRSF’s new AI-powered, graphene-based solution that can process the signals from the sensors and wirelessly transfers data to a cloud application (https://ibn.fm/zcERv).
Under the MOU, Brain Scientific would provide its proprietary data signal acquisition devices, NeuroCap(TM) and NeuroEEG(TM), for the Ehave platform. Ehave would integrate the devices to collect data from patients in real time and transfer that data into a cloud.
NeuroCap is a patented, disposable EEG headset with 22 pre-gelled electrodes that anyone can set up in five minutes or less to record a patient’s brain activity. The cap is compatible with third-party amplifiers and the device also works with NeuroEEG, a proprietary portable, wireless, 16-channel amplifier that can easily be deployed across a broad spectrum of settings also requires minimal training. The devices allow for raw EEG data to be instantly transferred to a cloud, which enables remote access and interpretation by neurologists. These low-cost, portable and wireless devices provide the same quality of signal as conventional EEG devices and could be employed both in clinical and commercial settings.
For example, one possible aspect of the collaboration could involve Ehave deploying NeuroCap and NeuroEEG in clinical settings with its partner healthcare providers such as psychiatrists, psychologists, psychotherapists and general practitioners. This would allow Ehave to collect the data representing electrophysiological changes in the brain before, during and after psychedelic drug administration.
The MOU may also potentially lead to establishing or partnering with a lab that could be equipped with NeuroCap and NeuroEEG devices to conduct market studies to study consumer behavior and psychology in markets and capture data on different brain-related physiological and mental disorders. Likely to begin in Australia, this application could be rolled out in other locations where Ehave has a presence.
The two collaborating companies will jointly own all data from any transactions arising from the MOU. Ehave will cover the testing and certification cost for products developed under the agreement and will receive full intellectual property rights, including the right to sell and distribute any such products, on a 50/50 split basis after all expenses, including research and development.
To learn more about this company, visit www.BrainScientific.com/Invest-Now.
NOTE TO INVESTORS: The latest news and updates relating to BRSF are available in the company’s newsroom at https://ibn.fm/BRSF
About MissionIR
MissionIR is primarily focused on strategic communications. We have executed countless communications programs to address the needs of companies ranging from start-ups to established industry leaders, gaining valuable experience and the expertise necessary to determine the most effective strategy for any given situation.
For more information, visit www.MissionIR.com
MissionIR (MIR)
Atlanta, Georgia
www.MissionIR.com
404.941.8975 Office
Editor@MissionIR.com
Please see full terms of use and disclaimers on the Mission Investor Relations website applicable to all content provided by MIR, wherever published or re-published: http://www.missionir.com/disclaimer.html
